Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725270 · ClinicalTrials.gov registry record · Phase 2
Treatment of Schizoaffective Disorder Using Mifepristone
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00725270: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00725270 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00725270, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.
Primary Outcome
Utilized the Positive Symptoms Subscale of the Brief Psychiatric Rating Scale is assess psychotic symptoms. Range for the subscale is 4-28, with 4 = no positive symptoms
Interventions
- DRUG Mifepristone
- DRUG Placebo Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1998-04 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Why NCT00725270 stopped before completion
NCT00725270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Mifepristone is the first listed.
NCT00725270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00725270 about?
NCT00725270 is a clinical study titled "Treatment of Schizoaffective Disorder Using Mifepristone". This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.
What is the current status of trial NCT00725270?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 1998-04. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00725270?
The interventions under investigation include: Mifepristone (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT00725270?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00725270's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia